Masoomeh Mohebbi1, Hassan Hashemi2, Soheila Asgari3, Sara Bigdeli1, Kambiz Ameli Zamani4. 1. Noor Ophthalmology Research Center, Noor Eye Hospital, No. 96 Esfandiar Blvd., Vali'asr Ave, Tehran, Iran. 2. Noor Ophthalmology Research Center, Noor Eye Hospital, No. 96 Esfandiar Blvd., Vali'asr Ave, Tehran, Iran. hhashemi@norc.ac.ir. 3. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 4. Farabi Eye Hospital, Department of Ophthalmology, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
PURPOSE: To determine the long-term results of femtosecond-assisted MyoRing implantation for the treatment of keratoconus. METHODS: In this prospective, non-randomized, interventional clinical study, 47 eyes of 46 patients with keratoconus grade 1 to 3 entered the study. For all patients, a MyoRing (Dioptex, GmbH, Austria) was implanted using a femtosecond laser (Femto LDV, Ziemer, Germany). RESULTS: At 18 months, mean uncorrected and best corrected visual acuity was 0.41 ± 0.19 logMAR, (P = 0.004) and 0.62 ± 0.22 logMAR (P < 0.001), and mean manifest refraction spherical equivalent was -0.38 ± 2.62D (P < 0.001). The central 3-mm maximum and mean keratometry decreased by 5.20 ± 3.06D and 4.77 ± 2.47D, respectively (both P < 0.001), and the 8-mm maximum keratometry decreased by 1.16 ± 5.50D (P = 0.185). Central and minimal corneal thickness showed an insignificant increase. Both corneal hysteresis and corneal resistance factor showed an insignificant decrease of about 0.13 mmHg. Endothelial cell count decreased by 215.43 ± 300.55 cell/mm(2) (P < 0.001). Twenty-six subjects (55.3 %) had halo vision at night and 24 subjects (51.1 %) had glare at night. CONCLUSIONS: Femtosecond-assisted intracorneal MyoRing implantation can be an appropriate treatment option in keratoconus patients with central corneal protrusion, but the incidence of optical disturbances can be relatively high.
PURPOSE: To determine the long-term results of femtosecond-assisted MyoRing implantation for the treatment of keratoconus. METHODS: In this prospective, non-randomized, interventional clinical study, 47 eyes of 46 patients with keratoconus grade 1 to 3 entered the study. For all patients, a MyoRing (Dioptex, GmbH, Austria) was implanted using a femtosecond laser (Femto LDV, Ziemer, Germany). RESULTS: At 18 months, mean uncorrected and best corrected visual acuity was 0.41 ± 0.19 logMAR, (P = 0.004) and 0.62 ± 0.22 logMAR (P < 0.001), and mean manifest refraction spherical equivalent was -0.38 ± 2.62D (P < 0.001). The central 3-mm maximum and mean keratometry decreased by 5.20 ± 3.06D and 4.77 ± 2.47D, respectively (both P < 0.001), and the 8-mm maximum keratometry decreased by 1.16 ± 5.50D (P = 0.185). Central and minimal corneal thickness showed an insignificant increase. Both corneal hysteresis and corneal resistance factor showed an insignificant decrease of about 0.13 mmHg. Endothelial cell count decreased by 215.43 ± 300.55 cell/mm(2) (P < 0.001). Twenty-six subjects (55.3 %) had halo vision at night and 24 subjects (51.1 %) had glare at night. CONCLUSIONS: Femtosecond-assisted intracorneal MyoRing implantation can be an appropriate treatment option in keratoconus patients with central corneal protrusion, but the incidence of optical disturbances can be relatively high.
Authors: Agnes I Takács; Illés Kovács; Kata Miháltz; Tamás Filkorn; Michael C Knorz; Zoltán Z Nagy Journal: J Refract Surg Date: 2012-05-16 Impact factor: 3.573
Authors: Alex W Cohen; Kenneth M Goins; John E Sutphin; George R Wandling; Michael D Wagoner Journal: Int Ophthalmol Date: 2010-09-23 Impact factor: 2.031
Authors: Miguel Ángel Ariza-Gracia; Julio Flecha-Lescún; Philippe Büchler; Begoña Calvo Journal: Transl Vis Sci Technol Date: 2020-10-21 Impact factor: 3.283